Review



primary human subcutaneous preadipocytes  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    ATCC primary human subcutaneous preadipocytes
    (A) Mouse <t>subcutaneous</t> adipose stromal cells (primary ASCs) differentiate into lipid-laden adipocytes after 10 days in culture. Images are oil red O (ORO) stained cells at day 0 (D0) or day 10 (D10) of adipocyte differentiation. Graph shows quantification of ORO accumulation over time. (B-D) Expression of adipocyte progenitor markers Cd34 (b), Pdgfra (c), and Cd24a (d) in mouse primary ASCs during proliferation (pro) or through differentiation. (E-F) Expression of preadipocyte markers Pparg (e) and Fabp4 (f) in mouse primary ASCs during proliferation (pro) or through differentiation. (G-H) Expression of Esr1 gene (g) or ERα protein (h) in mouse immortalized APCs during proliferation (pro) or through differentiation. (I) undifferentiated mouse primary ASCs treated with EtOH (Veh), E 2 , 4-OH tamoxifen (TAM) or E 2 +TAM. Images represent cells at day 4 of treatment. Scale=200µm. Inset graph represents cell number over the 4-day proliferation assay. Two-way ANOVA testing for main effects of treatment and time; interaction p<0.001. (J) ORO accumulation after 10 days of primary ASC differentiation; cells treated as in (i). Graph represents ORO absorbance on day 10. Scale=200µm. (K) undifferentiated primary human subcutaneous adipose stromal cells treated with EtOH (Veh), E 2 , 4-OH tamoxifen (TAM) or E 2 +TAM for 7.5 days. Two-way ANOVA testing for main effects of treatment or time; interaction p<0.001. Inset graph is cell number on the final day of proliferation; E 2 versus Veh p=0.011; E 2 +TAM vs E 2 p<0.001 by t-test. Images represent cells at day 7.5 of treatment. (L) ORO in human primary adipose stromal cells. (M) Representative FACS plots of mouse primary ASCs treated with EtOH (Veh), E 2 , or E 2 +4-OH tamoxifen (E 2 +TAM) for 48 hours and stained for Sca1 and CD24. (N-O) Percent of cells positive for Sca1 and CD24 (progenitors; n) or Sca1-positive, CD24-negative <t>(preadipocytes,</t> o) after treated as described in (m). T-tests determined significance.
    Primary Human Subcutaneous Preadipocytes, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 60 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary human subcutaneous preadipocytes/product/ATCC
    Average 95 stars, based on 60 article reviews
    primary human subcutaneous preadipocytes - by Bioz Stars, 2026-02
    95/100 stars

    Images

    1) Product Images from "Tamoxifen Targets Wisp2 to Impair Subcutaneous Adipocyte Progenitor Self-Renewal and Adipogenic Differentiation"

    Article Title: Tamoxifen Targets Wisp2 to Impair Subcutaneous Adipocyte Progenitor Self-Renewal and Adipogenic Differentiation

    Journal: bioRxiv

    doi: 10.64898/2025.12.21.695772

    (A) Mouse subcutaneous adipose stromal cells (primary ASCs) differentiate into lipid-laden adipocytes after 10 days in culture. Images are oil red O (ORO) stained cells at day 0 (D0) or day 10 (D10) of adipocyte differentiation. Graph shows quantification of ORO accumulation over time. (B-D) Expression of adipocyte progenitor markers Cd34 (b), Pdgfra (c), and Cd24a (d) in mouse primary ASCs during proliferation (pro) or through differentiation. (E-F) Expression of preadipocyte markers Pparg (e) and Fabp4 (f) in mouse primary ASCs during proliferation (pro) or through differentiation. (G-H) Expression of Esr1 gene (g) or ERα protein (h) in mouse immortalized APCs during proliferation (pro) or through differentiation. (I) undifferentiated mouse primary ASCs treated with EtOH (Veh), E 2 , 4-OH tamoxifen (TAM) or E 2 +TAM. Images represent cells at day 4 of treatment. Scale=200µm. Inset graph represents cell number over the 4-day proliferation assay. Two-way ANOVA testing for main effects of treatment and time; interaction p<0.001. (J) ORO accumulation after 10 days of primary ASC differentiation; cells treated as in (i). Graph represents ORO absorbance on day 10. Scale=200µm. (K) undifferentiated primary human subcutaneous adipose stromal cells treated with EtOH (Veh), E 2 , 4-OH tamoxifen (TAM) or E 2 +TAM for 7.5 days. Two-way ANOVA testing for main effects of treatment or time; interaction p<0.001. Inset graph is cell number on the final day of proliferation; E 2 versus Veh p=0.011; E 2 +TAM vs E 2 p<0.001 by t-test. Images represent cells at day 7.5 of treatment. (L) ORO in human primary adipose stromal cells. (M) Representative FACS plots of mouse primary ASCs treated with EtOH (Veh), E 2 , or E 2 +4-OH tamoxifen (E 2 +TAM) for 48 hours and stained for Sca1 and CD24. (N-O) Percent of cells positive for Sca1 and CD24 (progenitors; n) or Sca1-positive, CD24-negative (preadipocytes, o) after treated as described in (m). T-tests determined significance.
    Figure Legend Snippet: (A) Mouse subcutaneous adipose stromal cells (primary ASCs) differentiate into lipid-laden adipocytes after 10 days in culture. Images are oil red O (ORO) stained cells at day 0 (D0) or day 10 (D10) of adipocyte differentiation. Graph shows quantification of ORO accumulation over time. (B-D) Expression of adipocyte progenitor markers Cd34 (b), Pdgfra (c), and Cd24a (d) in mouse primary ASCs during proliferation (pro) or through differentiation. (E-F) Expression of preadipocyte markers Pparg (e) and Fabp4 (f) in mouse primary ASCs during proliferation (pro) or through differentiation. (G-H) Expression of Esr1 gene (g) or ERα protein (h) in mouse immortalized APCs during proliferation (pro) or through differentiation. (I) undifferentiated mouse primary ASCs treated with EtOH (Veh), E 2 , 4-OH tamoxifen (TAM) or E 2 +TAM. Images represent cells at day 4 of treatment. Scale=200µm. Inset graph represents cell number over the 4-day proliferation assay. Two-way ANOVA testing for main effects of treatment and time; interaction p<0.001. (J) ORO accumulation after 10 days of primary ASC differentiation; cells treated as in (i). Graph represents ORO absorbance on day 10. Scale=200µm. (K) undifferentiated primary human subcutaneous adipose stromal cells treated with EtOH (Veh), E 2 , 4-OH tamoxifen (TAM) or E 2 +TAM for 7.5 days. Two-way ANOVA testing for main effects of treatment or time; interaction p<0.001. Inset graph is cell number on the final day of proliferation; E 2 versus Veh p=0.011; E 2 +TAM vs E 2 p<0.001 by t-test. Images represent cells at day 7.5 of treatment. (L) ORO in human primary adipose stromal cells. (M) Representative FACS plots of mouse primary ASCs treated with EtOH (Veh), E 2 , or E 2 +4-OH tamoxifen (E 2 +TAM) for 48 hours and stained for Sca1 and CD24. (N-O) Percent of cells positive for Sca1 and CD24 (progenitors; n) or Sca1-positive, CD24-negative (preadipocytes, o) after treated as described in (m). T-tests determined significance.

    Techniques Used: Staining, Expressing, Proliferation Assay

    (A-B) Primary mouse ASCs were treated with EtOH (Veh), E 2 , or E 2 +4-OH tamoxifen (E 2 +TAM) prior to and during adipogenic differentiation for 10 days. (a). Schematic of adipogenesis was created with BioRender https://BioRender.com/az4hymd . Cells were then analyzed for Sca1+/CD24+ progenitors or Sca1+/CD24-preadipocytes by FACS (b). (C) Primary mouse subcutaneous ASCs were isolated from 6 different adult females (ages 20-24 weeks), and plated in media containing EtOH (Veh), E 2 , or E 2 +4-OH tamoxifen (E 2 +TAM). Cells were grown under these conditions and passaged each time they reached 80% confluence. The number of passages was recorded. For each treatment group, the experiment ended when cells no longer reached 80% confluence after 21 days and did not adhere to the plate with the subsequent passage, having reached the end of their proliferative lifespan. The passage number at this point was recorded for each experiment. At each passage, an aliquot of cells was plated for adipogenic differentiation and stained with oil red O (ORO). The absorbance of ORO was measured in technical triplicate wells from cells under each treatment at each passage. (D) Final passage numbers of primary ASCs were recorded under each treatment condition. Mann-Whitney test determined significance. (E) Representative quantification of ORO absorbance from key passage numbers, representing the final passage achieved for each treatment condition (E 2 +TAM=P6; Vehicle=P8; E 2 =P10). Images are phase contrast and ORO-stained plates from the respective passages.
    Figure Legend Snippet: (A-B) Primary mouse ASCs were treated with EtOH (Veh), E 2 , or E 2 +4-OH tamoxifen (E 2 +TAM) prior to and during adipogenic differentiation for 10 days. (a). Schematic of adipogenesis was created with BioRender https://BioRender.com/az4hymd . Cells were then analyzed for Sca1+/CD24+ progenitors or Sca1+/CD24-preadipocytes by FACS (b). (C) Primary mouse subcutaneous ASCs were isolated from 6 different adult females (ages 20-24 weeks), and plated in media containing EtOH (Veh), E 2 , or E 2 +4-OH tamoxifen (E 2 +TAM). Cells were grown under these conditions and passaged each time they reached 80% confluence. The number of passages was recorded. For each treatment group, the experiment ended when cells no longer reached 80% confluence after 21 days and did not adhere to the plate with the subsequent passage, having reached the end of their proliferative lifespan. The passage number at this point was recorded for each experiment. At each passage, an aliquot of cells was plated for adipogenic differentiation and stained with oil red O (ORO). The absorbance of ORO was measured in technical triplicate wells from cells under each treatment at each passage. (D) Final passage numbers of primary ASCs were recorded under each treatment condition. Mann-Whitney test determined significance. (E) Representative quantification of ORO absorbance from key passage numbers, representing the final passage achieved for each treatment condition (E 2 +TAM=P6; Vehicle=P8; E 2 =P10). Images are phase contrast and ORO-stained plates from the respective passages.

    Techniques Used: Isolation, Staining, MANN-WHITNEY

    (A) Venn diagram of genes that were higher in cells from obese versus lean female mice treated with E 2 , compared with genes that were lower after treatment of obese females with E 2 +tamoxifen (E 2 +TAM) or estrogen deprivation/withdrawal (EWD). Wisp2/Ccn5 was one of two genes in the overlap of all three gene lists. (B) UMAP showing the distribution and level of Wisp2/Ccn5 expression in primary mouse subcutaneous ASCs. (C) Violin plot showing the level of Wisp2 expression in each cluster, previously defined in Scalzo et al. (D) Bubble plot indicating the average expression level and percent positive cells for Wisp2 in each cluster and treatment group from primary mouse subcutaneous ASCs, as described in Scalzo, et al. (E-G) The percent of Wisp2 positive cells by treatment group in transitional progenitors (e), preadipocytes (f), and adipocyte regulatory cells (AREGs, g).
    Figure Legend Snippet: (A) Venn diagram of genes that were higher in cells from obese versus lean female mice treated with E 2 , compared with genes that were lower after treatment of obese females with E 2 +tamoxifen (E 2 +TAM) or estrogen deprivation/withdrawal (EWD). Wisp2/Ccn5 was one of two genes in the overlap of all three gene lists. (B) UMAP showing the distribution and level of Wisp2/Ccn5 expression in primary mouse subcutaneous ASCs. (C) Violin plot showing the level of Wisp2 expression in each cluster, previously defined in Scalzo et al. (D) Bubble plot indicating the average expression level and percent positive cells for Wisp2 in each cluster and treatment group from primary mouse subcutaneous ASCs, as described in Scalzo, et al. (E-G) The percent of Wisp2 positive cells by treatment group in transitional progenitors (e), preadipocytes (f), and adipocyte regulatory cells (AREGs, g).

    Techniques Used: Expressing

    (A) Expression of Wisp2 gene (left) and protein (right) in mouse immortalized APCs expressing shRNA for GFP (Con) or Wisp2 (W2KO). (B-D) Expression of adipocyte progenitor markers Cd34 (b), Pdgfra (c), or Cd24a (d) in Con and W2KO immortalized APCs during proliferation in standard growth media. (E) Cell number over 4 days in Con or W2KO populations treated with EtOH (veh), E 2 , or E 2 +4-OH tamoxifen (E 2 +TAM). 3-way ANOVA tested for main effects of time, treatment, and Wisp2 modification. (F) Oil red O (ORO) staining of Con or W2KO cells at day 0 of differentiation. Representative images on the left, quantification of ORO absorbance on the right. (G) Heatmap of expression of progenitor and preadipocyte markers in Con and W2KO cells treated with EtOH (veh) or E 2 for 48 hours. Data are expressed as fold change versus vehicle for each gene, showing 3 replicates per group. (H-I) Quantification of percent Sca1+/CD24+ progenitors (h) and Sca1+/CD24-preadipocytes (i) in Con or W2KO cells treated with vehicle or E 2 . T-tests determined significance.
    Figure Legend Snippet: (A) Expression of Wisp2 gene (left) and protein (right) in mouse immortalized APCs expressing shRNA for GFP (Con) or Wisp2 (W2KO). (B-D) Expression of adipocyte progenitor markers Cd34 (b), Pdgfra (c), or Cd24a (d) in Con and W2KO immortalized APCs during proliferation in standard growth media. (E) Cell number over 4 days in Con or W2KO populations treated with EtOH (veh), E 2 , or E 2 +4-OH tamoxifen (E 2 +TAM). 3-way ANOVA tested for main effects of time, treatment, and Wisp2 modification. (F) Oil red O (ORO) staining of Con or W2KO cells at day 0 of differentiation. Representative images on the left, quantification of ORO absorbance on the right. (G) Heatmap of expression of progenitor and preadipocyte markers in Con and W2KO cells treated with EtOH (veh) or E 2 for 48 hours. Data are expressed as fold change versus vehicle for each gene, showing 3 replicates per group. (H-I) Quantification of percent Sca1+/CD24+ progenitors (h) and Sca1+/CD24-preadipocytes (i) in Con or W2KO cells treated with vehicle or E 2 . T-tests determined significance.

    Techniques Used: Expressing, shRNA, Modification, Staining

    (A) Proliferation of mouse primary ASCs during 3 days of treatment EtOH (Veh), E 2 , E 2 +4-OH tamoxifen (E 2 +TAM), exogenous Wisp2 protein (Wisp2), or E 2 +TAM+Wisp2. Two-way ANOVA tested for main effects of time and treatment; interaction p<0.001. Inset shows relative cell number at the final time point. T-test determined significance. (B) oil red O accumulation after 10 days of differentiation of cells treated as in (a). T-tests determined significance at day 10. (C-E) Representative FACS plots showing cells treated as in (a) for 48 hours and stained for Sca1 and CD24. Percent of Sca1+/CD24+ progenitors shown in (d); percent of Sca1+/CD24-preadipocytes shown in (e). T-tests determined significance. (F-K) Expression of Cd34 (f), Pdgfra (g), Sca1/Ly6a (h), Cd24a (i), Pparg (j), or Fabp4 (k) in mouse primary ASCs treated as in (a) and differentiated for 10 days. Cells were treated for the duration of the differentiation assay, replenishing media every 2 days.
    Figure Legend Snippet: (A) Proliferation of mouse primary ASCs during 3 days of treatment EtOH (Veh), E 2 , E 2 +4-OH tamoxifen (E 2 +TAM), exogenous Wisp2 protein (Wisp2), or E 2 +TAM+Wisp2. Two-way ANOVA tested for main effects of time and treatment; interaction p<0.001. Inset shows relative cell number at the final time point. T-test determined significance. (B) oil red O accumulation after 10 days of differentiation of cells treated as in (a). T-tests determined significance at day 10. (C-E) Representative FACS plots showing cells treated as in (a) for 48 hours and stained for Sca1 and CD24. Percent of Sca1+/CD24+ progenitors shown in (d); percent of Sca1+/CD24-preadipocytes shown in (e). T-tests determined significance. (F-K) Expression of Cd34 (f), Pdgfra (g), Sca1/Ly6a (h), Cd24a (i), Pparg (j), or Fabp4 (k) in mouse primary ASCs treated as in (a) and differentiated for 10 days. Cells were treated for the duration of the differentiation assay, replenishing media every 2 days.

    Techniques Used: Staining, Expressing, Differentiation Assay

    (A) Expression of Wisp2 gene (left) and protein (right) in primary mouse subcutaneous ASCs from wild type (Con) or Wisp2 transgenic females (W2OE) both treated with Cre adenovirus in vitro. (B) Oil red O (ORO) accumulation in control and W2OE primary ASCs differentiated for 10 days in vitro. Graph shows ORO absorbance. (C) Proliferation of control or W2OE primary ASCs over 5 days, during treatment with EtOH (Veh), E 2 , or E 2 +4-OH tamoxifen (E 2 +TAM). Three-way ANOVA tested for main effects of time, treatment, or cell genotype. Interaction p-value <0.001. (D) Quantification of cell number after 5 days of proliferation as shown in (c). Statistical analysis is two-way ANOVA testing for main effects of treatment or cell genotype, with post-hoc analyses. (E-F) Quantification of Sca1+/CD24+ progenitors (e) or Sca1+/CD24-preadipocytes (f) after 2 days of treatment with EtOH (Veh), E 2 , or E 2 +TAM measured by FACS. (G) ORO accumulation in CON or W2OE cells treated with EtOH (Veh), E 2 , or E 2 +TAM for 10 days during differentiation. Graph represents quantification of ORO absorbance at day 10. T-tests determined significance.
    Figure Legend Snippet: (A) Expression of Wisp2 gene (left) and protein (right) in primary mouse subcutaneous ASCs from wild type (Con) or Wisp2 transgenic females (W2OE) both treated with Cre adenovirus in vitro. (B) Oil red O (ORO) accumulation in control and W2OE primary ASCs differentiated for 10 days in vitro. Graph shows ORO absorbance. (C) Proliferation of control or W2OE primary ASCs over 5 days, during treatment with EtOH (Veh), E 2 , or E 2 +4-OH tamoxifen (E 2 +TAM). Three-way ANOVA tested for main effects of time, treatment, or cell genotype. Interaction p-value <0.001. (D) Quantification of cell number after 5 days of proliferation as shown in (c). Statistical analysis is two-way ANOVA testing for main effects of treatment or cell genotype, with post-hoc analyses. (E-F) Quantification of Sca1+/CD24+ progenitors (e) or Sca1+/CD24-preadipocytes (f) after 2 days of treatment with EtOH (Veh), E 2 , or E 2 +TAM measured by FACS. (G) ORO accumulation in CON or W2OE cells treated with EtOH (Veh), E 2 , or E 2 +TAM for 10 days during differentiation. Graph represents quantification of ORO absorbance at day 10. T-tests determined significance.

    Techniques Used: Expressing, Transgenic Assay, In Vitro, Control



    Similar Products

    primary human subcutaneous preadipocytes  (ATCC)
    95
    ATCC primary human subcutaneous preadipocytes
    (A) Mouse <t>subcutaneous</t> adipose stromal cells (primary ASCs) differentiate into lipid-laden adipocytes after 10 days in culture. Images are oil red O (ORO) stained cells at day 0 (D0) or day 10 (D10) of adipocyte differentiation. Graph shows quantification of ORO accumulation over time. (B-D) Expression of adipocyte progenitor markers Cd34 (b), Pdgfra (c), and Cd24a (d) in mouse primary ASCs during proliferation (pro) or through differentiation. (E-F) Expression of preadipocyte markers Pparg (e) and Fabp4 (f) in mouse primary ASCs during proliferation (pro) or through differentiation. (G-H) Expression of Esr1 gene (g) or ERα protein (h) in mouse immortalized APCs during proliferation (pro) or through differentiation. (I) undifferentiated mouse primary ASCs treated with EtOH (Veh), E 2 , 4-OH tamoxifen (TAM) or E 2 +TAM. Images represent cells at day 4 of treatment. Scale=200µm. Inset graph represents cell number over the 4-day proliferation assay. Two-way ANOVA testing for main effects of treatment and time; interaction p<0.001. (J) ORO accumulation after 10 days of primary ASC differentiation; cells treated as in (i). Graph represents ORO absorbance on day 10. Scale=200µm. (K) undifferentiated primary human subcutaneous adipose stromal cells treated with EtOH (Veh), E 2 , 4-OH tamoxifen (TAM) or E 2 +TAM for 7.5 days. Two-way ANOVA testing for main effects of treatment or time; interaction p<0.001. Inset graph is cell number on the final day of proliferation; E 2 versus Veh p=0.011; E 2 +TAM vs E 2 p<0.001 by t-test. Images represent cells at day 7.5 of treatment. (L) ORO in human primary adipose stromal cells. (M) Representative FACS plots of mouse primary ASCs treated with EtOH (Veh), E 2 , or E 2 +4-OH tamoxifen (E 2 +TAM) for 48 hours and stained for Sca1 and CD24. (N-O) Percent of cells positive for Sca1 and CD24 (progenitors; n) or Sca1-positive, CD24-negative <t>(preadipocytes,</t> o) after treated as described in (m). T-tests determined significance.
    Primary Human Subcutaneous Preadipocytes, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary human subcutaneous preadipocytes/product/ATCC
    Average 95 stars, based on 1 article reviews
    primary human subcutaneous preadipocytes - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    primary human white preadiopcytes  (PromoCell)
    94
    PromoCell primary human white preadiopcytes
    (A) Mouse <t>subcutaneous</t> adipose stromal cells (primary ASCs) differentiate into lipid-laden adipocytes after 10 days in culture. Images are oil red O (ORO) stained cells at day 0 (D0) or day 10 (D10) of adipocyte differentiation. Graph shows quantification of ORO accumulation over time. (B-D) Expression of adipocyte progenitor markers Cd34 (b), Pdgfra (c), and Cd24a (d) in mouse primary ASCs during proliferation (pro) or through differentiation. (E-F) Expression of preadipocyte markers Pparg (e) and Fabp4 (f) in mouse primary ASCs during proliferation (pro) or through differentiation. (G-H) Expression of Esr1 gene (g) or ERα protein (h) in mouse immortalized APCs during proliferation (pro) or through differentiation. (I) undifferentiated mouse primary ASCs treated with EtOH (Veh), E 2 , 4-OH tamoxifen (TAM) or E 2 +TAM. Images represent cells at day 4 of treatment. Scale=200µm. Inset graph represents cell number over the 4-day proliferation assay. Two-way ANOVA testing for main effects of treatment and time; interaction p<0.001. (J) ORO accumulation after 10 days of primary ASC differentiation; cells treated as in (i). Graph represents ORO absorbance on day 10. Scale=200µm. (K) undifferentiated primary human subcutaneous adipose stromal cells treated with EtOH (Veh), E 2 , 4-OH tamoxifen (TAM) or E 2 +TAM for 7.5 days. Two-way ANOVA testing for main effects of treatment or time; interaction p<0.001. Inset graph is cell number on the final day of proliferation; E 2 versus Veh p=0.011; E 2 +TAM vs E 2 p<0.001 by t-test. Images represent cells at day 7.5 of treatment. (L) ORO in human primary adipose stromal cells. (M) Representative FACS plots of mouse primary ASCs treated with EtOH (Veh), E 2 , or E 2 +4-OH tamoxifen (E 2 +TAM) for 48 hours and stained for Sca1 and CD24. (N-O) Percent of cells positive for Sca1 and CD24 (progenitors; n) or Sca1-positive, CD24-negative <t>(preadipocytes,</t> o) after treated as described in (m). T-tests determined significance.
    Primary Human White Preadiopcytes, supplied by PromoCell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary human white preadiopcytes/product/PromoCell
    Average 94 stars, based on 1 article reviews
    primary human white preadiopcytes - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    primary human preadipocytes  (PromoCell)
    94
    PromoCell primary human preadipocytes
    (A) Mouse <t>subcutaneous</t> adipose stromal cells (primary ASCs) differentiate into lipid-laden adipocytes after 10 days in culture. Images are oil red O (ORO) stained cells at day 0 (D0) or day 10 (D10) of adipocyte differentiation. Graph shows quantification of ORO accumulation over time. (B-D) Expression of adipocyte progenitor markers Cd34 (b), Pdgfra (c), and Cd24a (d) in mouse primary ASCs during proliferation (pro) or through differentiation. (E-F) Expression of preadipocyte markers Pparg (e) and Fabp4 (f) in mouse primary ASCs during proliferation (pro) or through differentiation. (G-H) Expression of Esr1 gene (g) or ERα protein (h) in mouse immortalized APCs during proliferation (pro) or through differentiation. (I) undifferentiated mouse primary ASCs treated with EtOH (Veh), E 2 , 4-OH tamoxifen (TAM) or E 2 +TAM. Images represent cells at day 4 of treatment. Scale=200µm. Inset graph represents cell number over the 4-day proliferation assay. Two-way ANOVA testing for main effects of treatment and time; interaction p<0.001. (J) ORO accumulation after 10 days of primary ASC differentiation; cells treated as in (i). Graph represents ORO absorbance on day 10. Scale=200µm. (K) undifferentiated primary human subcutaneous adipose stromal cells treated with EtOH (Veh), E 2 , 4-OH tamoxifen (TAM) or E 2 +TAM for 7.5 days. Two-way ANOVA testing for main effects of treatment or time; interaction p<0.001. Inset graph is cell number on the final day of proliferation; E 2 versus Veh p=0.011; E 2 +TAM vs E 2 p<0.001 by t-test. Images represent cells at day 7.5 of treatment. (L) ORO in human primary adipose stromal cells. (M) Representative FACS plots of mouse primary ASCs treated with EtOH (Veh), E 2 , or E 2 +4-OH tamoxifen (E 2 +TAM) for 48 hours and stained for Sca1 and CD24. (N-O) Percent of cells positive for Sca1 and CD24 (progenitors; n) or Sca1-positive, CD24-negative <t>(preadipocytes,</t> o) after treated as described in (m). T-tests determined significance.
    Primary Human Preadipocytes, supplied by PromoCell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary human preadipocytes/product/PromoCell
    Average 94 stars, based on 1 article reviews
    primary human preadipocytes - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    cell culture primary human white preadipocytes  (PromoCell)
    94
    PromoCell cell culture primary human white preadipocytes
    (A) Mouse <t>subcutaneous</t> adipose stromal cells (primary ASCs) differentiate into lipid-laden adipocytes after 10 days in culture. Images are oil red O (ORO) stained cells at day 0 (D0) or day 10 (D10) of adipocyte differentiation. Graph shows quantification of ORO accumulation over time. (B-D) Expression of adipocyte progenitor markers Cd34 (b), Pdgfra (c), and Cd24a (d) in mouse primary ASCs during proliferation (pro) or through differentiation. (E-F) Expression of preadipocyte markers Pparg (e) and Fabp4 (f) in mouse primary ASCs during proliferation (pro) or through differentiation. (G-H) Expression of Esr1 gene (g) or ERα protein (h) in mouse immortalized APCs during proliferation (pro) or through differentiation. (I) undifferentiated mouse primary ASCs treated with EtOH (Veh), E 2 , 4-OH tamoxifen (TAM) or E 2 +TAM. Images represent cells at day 4 of treatment. Scale=200µm. Inset graph represents cell number over the 4-day proliferation assay. Two-way ANOVA testing for main effects of treatment and time; interaction p<0.001. (J) ORO accumulation after 10 days of primary ASC differentiation; cells treated as in (i). Graph represents ORO absorbance on day 10. Scale=200µm. (K) undifferentiated primary human subcutaneous adipose stromal cells treated with EtOH (Veh), E 2 , 4-OH tamoxifen (TAM) or E 2 +TAM for 7.5 days. Two-way ANOVA testing for main effects of treatment or time; interaction p<0.001. Inset graph is cell number on the final day of proliferation; E 2 versus Veh p=0.011; E 2 +TAM vs E 2 p<0.001 by t-test. Images represent cells at day 7.5 of treatment. (L) ORO in human primary adipose stromal cells. (M) Representative FACS plots of mouse primary ASCs treated with EtOH (Veh), E 2 , or E 2 +4-OH tamoxifen (E 2 +TAM) for 48 hours and stained for Sca1 and CD24. (N-O) Percent of cells positive for Sca1 and CD24 (progenitors; n) or Sca1-positive, CD24-negative <t>(preadipocytes,</t> o) after treated as described in (m). T-tests determined significance.
    Cell Culture Primary Human White Preadipocytes, supplied by PromoCell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cell culture primary human white preadipocytes/product/PromoCell
    Average 94 stars, based on 1 article reviews
    cell culture primary human white preadipocytes - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Mouse subcutaneous adipose stromal cells (primary ASCs) differentiate into lipid-laden adipocytes after 10 days in culture. Images are oil red O (ORO) stained cells at day 0 (D0) or day 10 (D10) of adipocyte differentiation. Graph shows quantification of ORO accumulation over time. (B-D) Expression of adipocyte progenitor markers Cd34 (b), Pdgfra (c), and Cd24a (d) in mouse primary ASCs during proliferation (pro) or through differentiation. (E-F) Expression of preadipocyte markers Pparg (e) and Fabp4 (f) in mouse primary ASCs during proliferation (pro) or through differentiation. (G-H) Expression of Esr1 gene (g) or ERα protein (h) in mouse immortalized APCs during proliferation (pro) or through differentiation. (I) undifferentiated mouse primary ASCs treated with EtOH (Veh), E 2 , 4-OH tamoxifen (TAM) or E 2 +TAM. Images represent cells at day 4 of treatment. Scale=200µm. Inset graph represents cell number over the 4-day proliferation assay. Two-way ANOVA testing for main effects of treatment and time; interaction p<0.001. (J) ORO accumulation after 10 days of primary ASC differentiation; cells treated as in (i). Graph represents ORO absorbance on day 10. Scale=200µm. (K) undifferentiated primary human subcutaneous adipose stromal cells treated with EtOH (Veh), E 2 , 4-OH tamoxifen (TAM) or E 2 +TAM for 7.5 days. Two-way ANOVA testing for main effects of treatment or time; interaction p<0.001. Inset graph is cell number on the final day of proliferation; E 2 versus Veh p=0.011; E 2 +TAM vs E 2 p<0.001 by t-test. Images represent cells at day 7.5 of treatment. (L) ORO in human primary adipose stromal cells. (M) Representative FACS plots of mouse primary ASCs treated with EtOH (Veh), E 2 , or E 2 +4-OH tamoxifen (E 2 +TAM) for 48 hours and stained for Sca1 and CD24. (N-O) Percent of cells positive for Sca1 and CD24 (progenitors; n) or Sca1-positive, CD24-negative (preadipocytes, o) after treated as described in (m). T-tests determined significance.

    Journal: bioRxiv

    Article Title: Tamoxifen Targets Wisp2 to Impair Subcutaneous Adipocyte Progenitor Self-Renewal and Adipogenic Differentiation

    doi: 10.64898/2025.12.21.695772

    Figure Lengend Snippet: (A) Mouse subcutaneous adipose stromal cells (primary ASCs) differentiate into lipid-laden adipocytes after 10 days in culture. Images are oil red O (ORO) stained cells at day 0 (D0) or day 10 (D10) of adipocyte differentiation. Graph shows quantification of ORO accumulation over time. (B-D) Expression of adipocyte progenitor markers Cd34 (b), Pdgfra (c), and Cd24a (d) in mouse primary ASCs during proliferation (pro) or through differentiation. (E-F) Expression of preadipocyte markers Pparg (e) and Fabp4 (f) in mouse primary ASCs during proliferation (pro) or through differentiation. (G-H) Expression of Esr1 gene (g) or ERα protein (h) in mouse immortalized APCs during proliferation (pro) or through differentiation. (I) undifferentiated mouse primary ASCs treated with EtOH (Veh), E 2 , 4-OH tamoxifen (TAM) or E 2 +TAM. Images represent cells at day 4 of treatment. Scale=200µm. Inset graph represents cell number over the 4-day proliferation assay. Two-way ANOVA testing for main effects of treatment and time; interaction p<0.001. (J) ORO accumulation after 10 days of primary ASC differentiation; cells treated as in (i). Graph represents ORO absorbance on day 10. Scale=200µm. (K) undifferentiated primary human subcutaneous adipose stromal cells treated with EtOH (Veh), E 2 , 4-OH tamoxifen (TAM) or E 2 +TAM for 7.5 days. Two-way ANOVA testing for main effects of treatment or time; interaction p<0.001. Inset graph is cell number on the final day of proliferation; E 2 versus Veh p=0.011; E 2 +TAM vs E 2 p<0.001 by t-test. Images represent cells at day 7.5 of treatment. (L) ORO in human primary adipose stromal cells. (M) Representative FACS plots of mouse primary ASCs treated with EtOH (Veh), E 2 , or E 2 +4-OH tamoxifen (E 2 +TAM) for 48 hours and stained for Sca1 and CD24. (N-O) Percent of cells positive for Sca1 and CD24 (progenitors; n) or Sca1-positive, CD24-negative (preadipocytes, o) after treated as described in (m). T-tests determined significance.

    Article Snippet: Primary human subcutaneous preadipocytes (PCS-210-01, ATCC) were cultured in fibroblast basal medium (ATCC PCS-201-030) with fibroblast low serum growth supplement (ATCC PCS-201-041).

    Techniques: Staining, Expressing, Proliferation Assay

    (A-B) Primary mouse ASCs were treated with EtOH (Veh), E 2 , or E 2 +4-OH tamoxifen (E 2 +TAM) prior to and during adipogenic differentiation for 10 days. (a). Schematic of adipogenesis was created with BioRender https://BioRender.com/az4hymd . Cells were then analyzed for Sca1+/CD24+ progenitors or Sca1+/CD24-preadipocytes by FACS (b). (C) Primary mouse subcutaneous ASCs were isolated from 6 different adult females (ages 20-24 weeks), and plated in media containing EtOH (Veh), E 2 , or E 2 +4-OH tamoxifen (E 2 +TAM). Cells were grown under these conditions and passaged each time they reached 80% confluence. The number of passages was recorded. For each treatment group, the experiment ended when cells no longer reached 80% confluence after 21 days and did not adhere to the plate with the subsequent passage, having reached the end of their proliferative lifespan. The passage number at this point was recorded for each experiment. At each passage, an aliquot of cells was plated for adipogenic differentiation and stained with oil red O (ORO). The absorbance of ORO was measured in technical triplicate wells from cells under each treatment at each passage. (D) Final passage numbers of primary ASCs were recorded under each treatment condition. Mann-Whitney test determined significance. (E) Representative quantification of ORO absorbance from key passage numbers, representing the final passage achieved for each treatment condition (E 2 +TAM=P6; Vehicle=P8; E 2 =P10). Images are phase contrast and ORO-stained plates from the respective passages.

    Journal: bioRxiv

    Article Title: Tamoxifen Targets Wisp2 to Impair Subcutaneous Adipocyte Progenitor Self-Renewal and Adipogenic Differentiation

    doi: 10.64898/2025.12.21.695772

    Figure Lengend Snippet: (A-B) Primary mouse ASCs were treated with EtOH (Veh), E 2 , or E 2 +4-OH tamoxifen (E 2 +TAM) prior to and during adipogenic differentiation for 10 days. (a). Schematic of adipogenesis was created with BioRender https://BioRender.com/az4hymd . Cells were then analyzed for Sca1+/CD24+ progenitors or Sca1+/CD24-preadipocytes by FACS (b). (C) Primary mouse subcutaneous ASCs were isolated from 6 different adult females (ages 20-24 weeks), and plated in media containing EtOH (Veh), E 2 , or E 2 +4-OH tamoxifen (E 2 +TAM). Cells were grown under these conditions and passaged each time they reached 80% confluence. The number of passages was recorded. For each treatment group, the experiment ended when cells no longer reached 80% confluence after 21 days and did not adhere to the plate with the subsequent passage, having reached the end of their proliferative lifespan. The passage number at this point was recorded for each experiment. At each passage, an aliquot of cells was plated for adipogenic differentiation and stained with oil red O (ORO). The absorbance of ORO was measured in technical triplicate wells from cells under each treatment at each passage. (D) Final passage numbers of primary ASCs were recorded under each treatment condition. Mann-Whitney test determined significance. (E) Representative quantification of ORO absorbance from key passage numbers, representing the final passage achieved for each treatment condition (E 2 +TAM=P6; Vehicle=P8; E 2 =P10). Images are phase contrast and ORO-stained plates from the respective passages.

    Article Snippet: Primary human subcutaneous preadipocytes (PCS-210-01, ATCC) were cultured in fibroblast basal medium (ATCC PCS-201-030) with fibroblast low serum growth supplement (ATCC PCS-201-041).

    Techniques: Isolation, Staining, MANN-WHITNEY

    (A) Venn diagram of genes that were higher in cells from obese versus lean female mice treated with E 2 , compared with genes that were lower after treatment of obese females with E 2 +tamoxifen (E 2 +TAM) or estrogen deprivation/withdrawal (EWD). Wisp2/Ccn5 was one of two genes in the overlap of all three gene lists. (B) UMAP showing the distribution and level of Wisp2/Ccn5 expression in primary mouse subcutaneous ASCs. (C) Violin plot showing the level of Wisp2 expression in each cluster, previously defined in Scalzo et al. (D) Bubble plot indicating the average expression level and percent positive cells for Wisp2 in each cluster and treatment group from primary mouse subcutaneous ASCs, as described in Scalzo, et al. (E-G) The percent of Wisp2 positive cells by treatment group in transitional progenitors (e), preadipocytes (f), and adipocyte regulatory cells (AREGs, g).

    Journal: bioRxiv

    Article Title: Tamoxifen Targets Wisp2 to Impair Subcutaneous Adipocyte Progenitor Self-Renewal and Adipogenic Differentiation

    doi: 10.64898/2025.12.21.695772

    Figure Lengend Snippet: (A) Venn diagram of genes that were higher in cells from obese versus lean female mice treated with E 2 , compared with genes that were lower after treatment of obese females with E 2 +tamoxifen (E 2 +TAM) or estrogen deprivation/withdrawal (EWD). Wisp2/Ccn5 was one of two genes in the overlap of all three gene lists. (B) UMAP showing the distribution and level of Wisp2/Ccn5 expression in primary mouse subcutaneous ASCs. (C) Violin plot showing the level of Wisp2 expression in each cluster, previously defined in Scalzo et al. (D) Bubble plot indicating the average expression level and percent positive cells for Wisp2 in each cluster and treatment group from primary mouse subcutaneous ASCs, as described in Scalzo, et al. (E-G) The percent of Wisp2 positive cells by treatment group in transitional progenitors (e), preadipocytes (f), and adipocyte regulatory cells (AREGs, g).

    Article Snippet: Primary human subcutaneous preadipocytes (PCS-210-01, ATCC) were cultured in fibroblast basal medium (ATCC PCS-201-030) with fibroblast low serum growth supplement (ATCC PCS-201-041).

    Techniques: Expressing

    (A) Expression of Wisp2 gene (left) and protein (right) in mouse immortalized APCs expressing shRNA for GFP (Con) or Wisp2 (W2KO). (B-D) Expression of adipocyte progenitor markers Cd34 (b), Pdgfra (c), or Cd24a (d) in Con and W2KO immortalized APCs during proliferation in standard growth media. (E) Cell number over 4 days in Con or W2KO populations treated with EtOH (veh), E 2 , or E 2 +4-OH tamoxifen (E 2 +TAM). 3-way ANOVA tested for main effects of time, treatment, and Wisp2 modification. (F) Oil red O (ORO) staining of Con or W2KO cells at day 0 of differentiation. Representative images on the left, quantification of ORO absorbance on the right. (G) Heatmap of expression of progenitor and preadipocyte markers in Con and W2KO cells treated with EtOH (veh) or E 2 for 48 hours. Data are expressed as fold change versus vehicle for each gene, showing 3 replicates per group. (H-I) Quantification of percent Sca1+/CD24+ progenitors (h) and Sca1+/CD24-preadipocytes (i) in Con or W2KO cells treated with vehicle or E 2 . T-tests determined significance.

    Journal: bioRxiv

    Article Title: Tamoxifen Targets Wisp2 to Impair Subcutaneous Adipocyte Progenitor Self-Renewal and Adipogenic Differentiation

    doi: 10.64898/2025.12.21.695772

    Figure Lengend Snippet: (A) Expression of Wisp2 gene (left) and protein (right) in mouse immortalized APCs expressing shRNA for GFP (Con) or Wisp2 (W2KO). (B-D) Expression of adipocyte progenitor markers Cd34 (b), Pdgfra (c), or Cd24a (d) in Con and W2KO immortalized APCs during proliferation in standard growth media. (E) Cell number over 4 days in Con or W2KO populations treated with EtOH (veh), E 2 , or E 2 +4-OH tamoxifen (E 2 +TAM). 3-way ANOVA tested for main effects of time, treatment, and Wisp2 modification. (F) Oil red O (ORO) staining of Con or W2KO cells at day 0 of differentiation. Representative images on the left, quantification of ORO absorbance on the right. (G) Heatmap of expression of progenitor and preadipocyte markers in Con and W2KO cells treated with EtOH (veh) or E 2 for 48 hours. Data are expressed as fold change versus vehicle for each gene, showing 3 replicates per group. (H-I) Quantification of percent Sca1+/CD24+ progenitors (h) and Sca1+/CD24-preadipocytes (i) in Con or W2KO cells treated with vehicle or E 2 . T-tests determined significance.

    Article Snippet: Primary human subcutaneous preadipocytes (PCS-210-01, ATCC) were cultured in fibroblast basal medium (ATCC PCS-201-030) with fibroblast low serum growth supplement (ATCC PCS-201-041).

    Techniques: Expressing, shRNA, Modification, Staining

    (A) Proliferation of mouse primary ASCs during 3 days of treatment EtOH (Veh), E 2 , E 2 +4-OH tamoxifen (E 2 +TAM), exogenous Wisp2 protein (Wisp2), or E 2 +TAM+Wisp2. Two-way ANOVA tested for main effects of time and treatment; interaction p<0.001. Inset shows relative cell number at the final time point. T-test determined significance. (B) oil red O accumulation after 10 days of differentiation of cells treated as in (a). T-tests determined significance at day 10. (C-E) Representative FACS plots showing cells treated as in (a) for 48 hours and stained for Sca1 and CD24. Percent of Sca1+/CD24+ progenitors shown in (d); percent of Sca1+/CD24-preadipocytes shown in (e). T-tests determined significance. (F-K) Expression of Cd34 (f), Pdgfra (g), Sca1/Ly6a (h), Cd24a (i), Pparg (j), or Fabp4 (k) in mouse primary ASCs treated as in (a) and differentiated for 10 days. Cells were treated for the duration of the differentiation assay, replenishing media every 2 days.

    Journal: bioRxiv

    Article Title: Tamoxifen Targets Wisp2 to Impair Subcutaneous Adipocyte Progenitor Self-Renewal and Adipogenic Differentiation

    doi: 10.64898/2025.12.21.695772

    Figure Lengend Snippet: (A) Proliferation of mouse primary ASCs during 3 days of treatment EtOH (Veh), E 2 , E 2 +4-OH tamoxifen (E 2 +TAM), exogenous Wisp2 protein (Wisp2), or E 2 +TAM+Wisp2. Two-way ANOVA tested for main effects of time and treatment; interaction p<0.001. Inset shows relative cell number at the final time point. T-test determined significance. (B) oil red O accumulation after 10 days of differentiation of cells treated as in (a). T-tests determined significance at day 10. (C-E) Representative FACS plots showing cells treated as in (a) for 48 hours and stained for Sca1 and CD24. Percent of Sca1+/CD24+ progenitors shown in (d); percent of Sca1+/CD24-preadipocytes shown in (e). T-tests determined significance. (F-K) Expression of Cd34 (f), Pdgfra (g), Sca1/Ly6a (h), Cd24a (i), Pparg (j), or Fabp4 (k) in mouse primary ASCs treated as in (a) and differentiated for 10 days. Cells were treated for the duration of the differentiation assay, replenishing media every 2 days.

    Article Snippet: Primary human subcutaneous preadipocytes (PCS-210-01, ATCC) were cultured in fibroblast basal medium (ATCC PCS-201-030) with fibroblast low serum growth supplement (ATCC PCS-201-041).

    Techniques: Staining, Expressing, Differentiation Assay

    (A) Expression of Wisp2 gene (left) and protein (right) in primary mouse subcutaneous ASCs from wild type (Con) or Wisp2 transgenic females (W2OE) both treated with Cre adenovirus in vitro. (B) Oil red O (ORO) accumulation in control and W2OE primary ASCs differentiated for 10 days in vitro. Graph shows ORO absorbance. (C) Proliferation of control or W2OE primary ASCs over 5 days, during treatment with EtOH (Veh), E 2 , or E 2 +4-OH tamoxifen (E 2 +TAM). Three-way ANOVA tested for main effects of time, treatment, or cell genotype. Interaction p-value <0.001. (D) Quantification of cell number after 5 days of proliferation as shown in (c). Statistical analysis is two-way ANOVA testing for main effects of treatment or cell genotype, with post-hoc analyses. (E-F) Quantification of Sca1+/CD24+ progenitors (e) or Sca1+/CD24-preadipocytes (f) after 2 days of treatment with EtOH (Veh), E 2 , or E 2 +TAM measured by FACS. (G) ORO accumulation in CON or W2OE cells treated with EtOH (Veh), E 2 , or E 2 +TAM for 10 days during differentiation. Graph represents quantification of ORO absorbance at day 10. T-tests determined significance.

    Journal: bioRxiv

    Article Title: Tamoxifen Targets Wisp2 to Impair Subcutaneous Adipocyte Progenitor Self-Renewal and Adipogenic Differentiation

    doi: 10.64898/2025.12.21.695772

    Figure Lengend Snippet: (A) Expression of Wisp2 gene (left) and protein (right) in primary mouse subcutaneous ASCs from wild type (Con) or Wisp2 transgenic females (W2OE) both treated with Cre adenovirus in vitro. (B) Oil red O (ORO) accumulation in control and W2OE primary ASCs differentiated for 10 days in vitro. Graph shows ORO absorbance. (C) Proliferation of control or W2OE primary ASCs over 5 days, during treatment with EtOH (Veh), E 2 , or E 2 +4-OH tamoxifen (E 2 +TAM). Three-way ANOVA tested for main effects of time, treatment, or cell genotype. Interaction p-value <0.001. (D) Quantification of cell number after 5 days of proliferation as shown in (c). Statistical analysis is two-way ANOVA testing for main effects of treatment or cell genotype, with post-hoc analyses. (E-F) Quantification of Sca1+/CD24+ progenitors (e) or Sca1+/CD24-preadipocytes (f) after 2 days of treatment with EtOH (Veh), E 2 , or E 2 +TAM measured by FACS. (G) ORO accumulation in CON or W2OE cells treated with EtOH (Veh), E 2 , or E 2 +TAM for 10 days during differentiation. Graph represents quantification of ORO absorbance at day 10. T-tests determined significance.

    Article Snippet: Primary human subcutaneous preadipocytes (PCS-210-01, ATCC) were cultured in fibroblast basal medium (ATCC PCS-201-030) with fibroblast low serum growth supplement (ATCC PCS-201-041).

    Techniques: Expressing, Transgenic Assay, In Vitro, Control